JPH0622794A - Indicator for measuring peroxide-decomposable substance and reagent kid - Google Patents
Indicator for measuring peroxide-decomposable substance and reagent kidInfo
- Publication number
- JPH0622794A JPH0622794A JP8490892A JP8490892A JPH0622794A JP H0622794 A JPH0622794 A JP H0622794A JP 8490892 A JP8490892 A JP 8490892A JP 8490892 A JP8490892 A JP 8490892A JP H0622794 A JPH0622794 A JP H0622794A
- Authority
- JP
- Japan
- Prior art keywords
- indicator
- peroxide
- benzidine
- substance
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 title claims abstract description 36
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 12
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 claims abstract description 25
- 150000002978 peroxides Chemical class 0.000 claims abstract description 21
- 239000002904 solvent Substances 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 102000003992 Peroxidases Human genes 0.000 claims description 11
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 238000011161 development Methods 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 239000012736 aqueous medium Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 abstract description 8
- 239000003086 colorant Substances 0.000 abstract description 4
- 238000004321 preservation Methods 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- -1 N'-substituted benzidine Chemical class 0.000 description 4
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- XMNIXWIUMCBBBL-UHFFFAOYSA-N 2-(2-phenylpropan-2-ylperoxy)propan-2-ylbenzene Chemical compound C=1C=CC=CC=1C(C)(C)OOC(C)(C)C1=CC=CC=C1 XMNIXWIUMCBBBL-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- NUIURNJTPRWVAP-UHFFFAOYSA-N 3,3'-Dimethylbenzidine Chemical compound C1=C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 NUIURNJTPRWVAP-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 description 2
- 240000003291 Armoracia rusticana Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- RQALKBLYTUKBFV-UHFFFAOYSA-N 1,4-dioxa-7-thiaspiro[4.4]nonane Chemical compound O1CCOC11CSCC1 RQALKBLYTUKBFV-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- PAOHAQSLJSMLAT-UHFFFAOYSA-N 1-butylperoxybutane Chemical compound CCCCOOCCCC PAOHAQSLJSMLAT-UHFFFAOYSA-N 0.000 description 1
- DBTGFWMBFZBBEF-UHFFFAOYSA-N 2,4-dimethylpentane-2,4-diol Chemical compound CC(C)(O)CC(C)(C)O DBTGFWMBFZBBEF-UHFFFAOYSA-N 0.000 description 1
- ZWNMRZQYWRLGMM-UHFFFAOYSA-N 2,5-dimethylhexane-2,5-diol Chemical compound CC(C)(O)CCC(C)(C)O ZWNMRZQYWRLGMM-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 1
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 1
- SNCJAJRILVFXAE-UHFFFAOYSA-N 9h-fluorene-2,7-diamine Chemical compound NC1=CC=C2C3=CC=C(N)C=C3CC2=C1 SNCJAJRILVFXAE-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011981 development test Methods 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- UZLGHNUASUZUOR-UHFFFAOYSA-L dipotassium;3-carboxy-3-hydroxypentanedioate Chemical compound [K+].[K+].OC(=O)CC(O)(C([O-])=O)CC([O-])=O UZLGHNUASUZUOR-UHFFFAOYSA-L 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- UHCGLDSRFKGERO-UHFFFAOYSA-N strontium peroxide Chemical compound [Sr+2].[O-][O-] UHCGLDSRFKGERO-UHFFFAOYSA-N 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は酵素免疫測定法、生化学
測定法等の分野に利用され、ペルオキシダーゼなどの過
酸化物分解性物質を測定する目的で使用されるベンジジ
ン系発色剤含有指示薬及びこの指示薬を含む試薬キット
に関する。FIELD OF THE INVENTION The present invention is used in the fields of enzyme immunoassay, biochemical assay, etc., and is used as an indicator containing a benzidine color-developing agent for the purpose of measuring a peroxide decomposable substance such as peroxidase. The present invention relates to a reagent kit containing this indicator.
【0002】[0002]
【従来の技術】従来、酵素免疫測定法等の分野において
は、水性媒体中に過酸化水素等の過酸化物及びベンジジ
ン系発色剤を溶解させた指示薬が知られている。この指
示薬は、過酸化物分解性物質やこの物質で標識された物
質等を測定対象として使用するものであり、この過酸化
物分解性物質の測定を、この物質と過酸化物との反応に
伴うベンジジン系発色剤の発色により行うものである。2. Description of the Related Art Conventionally, in the field of enzyme immunoassay and the like, an indicator in which a peroxide such as hydrogen peroxide and a benzidine color former are dissolved in an aqueous medium is known. This indicator uses a peroxide decomposable substance or a substance labeled with this substance as a measurement target, and the measurement of this peroxide decomposable substance is performed in the reaction between this substance and peroxide. This is performed by color development of the accompanying benzidine-based color developing agent.
【0003】この指示薬に用いられるベンジジン系発色
剤は、更に以前より用いられているオルトフェニレンジ
アミン等の発色剤と異なり、低毒性のものもあり、高感
度であるという利点があるが、水には僅かしか溶解せ
ず、低温での保存安定性に問題があった。そのため、従
来メタノール、1−メチル−2−ピロリドン等の有機溶
剤を含む水溶液に、ベンジジン系発色剤を高濃度溶解さ
せ、使用前に緩衝液等で適当な濃度に希釈して使用され
ていた(例えば、特開昭63−199270、特開昭6
2−500882、特開昭56−76048、特開昭4
9−133092号公報)。Unlike the color formers such as ortho-phenylenediamine, which have been used for a long time, the benzidine-based color formers used as the indicator have low toxicity and have the advantage of high sensitivity, but they have the advantage of being highly sensitive to water. Dissolves only slightly and has a problem in storage stability at low temperatures. Therefore, conventionally, a benzidine-based color-developing agent was dissolved at a high concentration in an aqueous solution containing an organic solvent such as methanol or 1-methyl-2-pyrrolidone, and it was used after being diluted to an appropriate concentration with a buffer solution or the like before use ( For example, JP-A 63-199270 and JP-A 6-1994
2-500882, JP-A-56-76048, JP-A-4
9-133092).
【0004】[0004]
【発明が解決しようとする課題】しかしながら、従来の
有機溶剤を多く含むベンジジン系指示薬はこの指示薬を
調製する前の有機溶剤が高濃度の時は比較的安定である
のに対し、使用濃度に希釈して指示薬とした後は不安定
で、発色剤が析出する、ペルオキシダーゼ等の過酸化物
分解性物質不存在にも拘らず発色する(ブランク値が上
昇する)、発色度が低下する等の問題があり、使用濃度
で長期間保存出来ないことから、使用直前に調製するこ
とが必要であった。これらのことは、酵素免疫測定等の
分析手段としてその有用性を著しく制限するものであ
る。本発明はベンジジン系発色剤を測定用指示薬として
使用する際、感度が優れ、保存安定性の良好な水性媒体
を提供することを目的とするものである。However, conventional benzidine-based indicators containing a large amount of organic solvent are relatively stable when the concentration of the organic solvent before preparation of the indicator is high, but dilute to the use concentration. After being used as an indicator, it is unstable, and a color former precipitates, color develops despite the absence of peroxide-decomposable substances such as peroxidase (blank value increases), and the degree of color development decreases. Since it cannot be stored for a long time at the use concentration, it was necessary to prepare it just before use. These things severely limit their usefulness as analysis means such as enzyme immunoassay. An object of the present invention is to provide an aqueous medium having excellent sensitivity and good storage stability when using a benzidine-based color former as an indicator for measurement.
【0005】[0005]
【課題を解決するための手段】本発明者らは上記目的を
達成すべく鋭意検討した結果、ベンジジン系発色剤の可
溶化剤として、特定の化合物を用いることにより、指示
薬として長期保存でき、また、低濃度の過酸化物分解性
物質が正確に測定できる指示薬が得られることを見いだ
し、本発明に到達した。即ち、本発明は下記〈1〉及び
〈2〉により構成される。 〈1〉水性媒体中に過酸化物(A)及びベンジジン系発
色剤(B)を溶解させてなり、過酸化物分解性物質
(C)の測定を(A)と(C)との反応に伴う(B)の
発色により行うことができる指示薬において、更に下記
一般式(1)〜(4)で表される化合物から選ばれる少
なくとも1種の可溶化剤(D)を含有することを特徴と
する過酸化物分解性物質測定用指示薬。 (式中、R1はそれぞれ独立に炭素数2〜4のアルキレ
ン基、R2は炭素数1〜4のアルキル基、 R3は水素又
は炭素数1〜4のアルキル基、 R4は炭素数1〜4のア
ルキレン基、R5はそれぞれ独立に水素または炭素数1
〜4のアルキル基、mは2〜20の整数、nは1〜20
の整数、X+Y+Zは1〜20の整数である) 〈2〉過酸化物分解性物質(C)もしくは(C)で標識
された化合物を構成品として含む試薬キットにおいて、
少なくとも上記〈1〉に記載の指示薬もしくはこの指示
薬の各成分を共に構成品とすることを特徴とする試薬キ
ット。Means for Solving the Problems The inventors of the present invention have conducted extensive studies to achieve the above object, and as a result, by using a specific compound as a solubilizing agent for a benzidine-based color former, it can be stored for a long time as an indicator, and The inventors have found that an indicator capable of accurately measuring a low-concentration peroxide-decomposing substance can be obtained, and have reached the present invention. That is, the present invention comprises the following <1> and <2>. <1> A peroxide (A) and a benzidine-based color former (B) are dissolved in an aqueous medium, and the peroxide decomposable substance (C) is measured by the reaction between (A) and (C). The indicator which can be carried out by the color development of (B), further comprising at least one solubilizer (D) selected from compounds represented by the following general formulas (1) to (4): Indicator for measuring peroxide-decomposable substances. (In the formula, R 1 is each independently an alkylene group having 2 to 4 carbon atoms, R 2 is an alkyl group having 1 to 4 carbon atoms, R 3 is hydrogen or an alkyl group having 1 to 4 carbon atoms, and R 4 is a carbon number. 1-4 alkylene groups, R 5 is independently hydrogen or C 1
~ 4 alkyl group, m is an integer of 2-20, n is 1-20
And an integer of X + Y + Z is an integer of 1 to 20) <2> A reagent kit containing a peroxide-decomposable substance (C) or a compound labeled with (C) as a component,
A reagent kit comprising at least the indicator according to the above <1> or each component of the indicator together as a component.
【0006】本発明において、過酸化物(A)として
は、例えば、過酸化水素、無機過酸化物(過ホウ酸ナト
リウム、過ホウ酸カリウム等)、有機過酸化物(クメン
パーオキシド、t−ブチルパーオキシド、ジイソプロピ
ルベンゼンパーオキシド、2,5−ジメチルヘキサン−
2,5−パーオキシド等)が挙げられる。これらのうち
好ましいものは過酸化水素である。In the present invention, examples of the peroxide (A) include hydrogen peroxide, inorganic peroxides (sodium perborate, potassium perborate, etc.), organic peroxides (cumene peroxide, t-). Butyl peroxide, diisopropylbenzene peroxide, 2,5-dimethylhexane-
2,5-peroxide and the like). Preferred among these is hydrogen peroxide.
【0007】本発明において、ベンジジン系発色剤
(B)としては、例えば、ベンジジン、核置換ベンジジ
ン、N−,N’−置換ベンジジン及びこれらの塩酸塩等
の従来公知の各種ベンジジン系発色剤が挙げられる。
(B)の具体例としては、ベンジジン、ベンジジン・2
HCl、O−トリジン、O−トリジン・2HCl、O−
ジアニシジン、3,3’,5,5’−テトラ(低級アル
キル)ベンジジン、3,3’,5,5’−テトラ(低級
アルキル)ベンジジン・2HCl・2H2O、2,7−
ジアミノフルオレン及びこれらの混合物が挙げられる。
ここで用いる用語「低級アルキル」はメチル、エチル、
n−プロピル及びイソプロピル、並びに種々のブチル、
ペンチル及びヘキシル異性体を初めとする炭素数1〜6
のアルキル基を意味する。これらのうち好ましいものは
3,3’,5,5’−テトラ(低級アルキル)ベンジジ
ンで、特に好ましいものは、3,3’,5,5’−テト
ラメチルベンジジンである。これらのベンジジン系発色
剤(B)の調製は、塩の形のものはそのまま水性媒体中
に添加することができ、塩の形でないものは少量の有機
溶剤に溶解して水性媒体中に添加するとよい。In the present invention, examples of the benzidine-based color former (B) include various conventionally known benzidine-based color formers such as benzidine, nucleus-substituted benzidine, N-, N'-substituted benzidine and their hydrochlorides. To be
Specific examples of (B) include benzidine and benzidine.2.
HCl, O-Tolidine, O-Tolidine.2HCl, O-
Dianisidine, 3,3 ', 5,5'-tetra (lower alkyl) benzidine, 3,3', 5,5'-tetra (lower alkyl) benzidine · 2HCl · 2H 2 O, 2,7-
Diaminofluorene and mixtures thereof may be mentioned.
As used herein, the term "lower alkyl" is methyl, ethyl,
n-propyl and isopropyl, and various butyls,
1 to 6 carbon atoms including pentyl and hexyl isomers
Means an alkyl group. Of these, preferred is 3,3 ', 5,5'-tetra (lower alkyl) benzidine, and particularly preferred is 3,3', 5,5'-tetramethylbenzidine. In the preparation of these benzidine-based color formers (B), the salt form can be added as it is to an aqueous medium, and the non-salt form can be dissolved in a small amount of an organic solvent and added to the aqueous medium. Good.
【0008】本発明において、過酸化物分解性物質
(C)としては、例えば、ペルオキシダーゼ(西洋ワサ
ビ、牛乳、白血球から抽出したペルオキシダーゼ)また
はカタラーゼ等の酵素類、該酵素と同様の作用を現わす
ヘモグロビン、チトクローム−C及びそれらの誘導体、
紫外線、有機及び無機金属塩が挙げられる。これらのう
ち好ましいものは、ペルオキシダーゼであり、特に好ま
しいものは、西洋ワサビから抽出したペルオキシダーゼ
である。In the present invention, as the peroxide decomposing substance (C), for example, enzymes such as peroxidase (peroxidase extracted from horseradish, milk, leukocytes) or catalase, and the same action as the enzyme is exhibited. Hemoglobin, cytochrome-C and their derivatives,
UV, organic and inorganic metal salts are mentioned. Among these, preferred is peroxidase, and particularly preferred is peroxidase extracted from horseradish.
【0009】本発明において、可溶化剤(D)として
は、下記一般式 (式中、R1はそれぞれ独立に炭素数2〜4のアルキレ
ン基、R2は炭素数1〜4のアルキル基、 R3は水素又
は炭素数1〜4のアルキル基、 R4は炭素数1〜4のア
ルキレン基、R5はそれぞれ独立に水素または炭素数1
〜4のアルキル基、mは2〜20の整数、nは1〜20
の整数、X+Y+Zは1〜20の整数である)からなる
群より選ばれる1種以上の化合物が挙げられる。In the present invention, the solubilizer (D) is represented by the following general formula (In the formula, R 1 is each independently an alkylene group having 2 to 4 carbon atoms, R 2 is an alkyl group having 1 to 4 carbon atoms, R 3 is hydrogen or an alkyl group having 1 to 4 carbon atoms, and R 4 is a carbon number. 1-4 alkylene groups, R 5 is independently hydrogen or C 1
~ 4 alkyl group, m is an integer of 2-20, n is 1-20
And an integer of X + Y + Z is an integer of 1 to 20).
【0010】本発明において、可溶化剤(D)のうち一
般式(1)で表される化合物としては、 ジエチレング
リコール、トリエチレングリコール、テトラエチレング
リコール、ポリエチレングリコール200〜800(重
量平均分子量200〜800のオキシエチレン付加重合
物)、ジプロピレングリコール、トリプロピレングリコ
ール、ポリプロピレングリコール200〜800(重量
平均分子量200〜800のオキシプロピレン付加重合
物)、ポリオキシエチレン・ポリオキシプロピレン共重
合物等が挙げられる。これらのうち好ましいものは、ト
リエチレングリコール、テトラエチレングリコール、ポ
リエチレングリコール200〜800である。In the present invention, the compound represented by the general formula (1) in the solubilizer (D) includes diethylene glycol, triethylene glycol, tetraethylene glycol, polyethylene glycol 200 to 800 (weight average molecular weight 200 to 800). Oxyethylene addition polymer), dipropylene glycol, tripropylene glycol, polypropylene glycol 200 to 800 (oxypropylene addition polymer having a weight average molecular weight of 200 to 800), polyoxyethylene / polyoxypropylene copolymer, and the like. . Of these, preferred are triethylene glycol, tetraethylene glycol, and polyethylene glycols 200 to 800.
【0011】(D)のうち一般式(2)で表される化合
物としては、上記のエチレングリコール類もしくはプロ
ピレングリコール類の、モノもしくはジアルキル(例、
メチル、エチル、プロピル、ブチル)エーテル、n−ブ
タノールのエチレンオキシド及びプロピレンオキシド共
重合物等が挙げられる。これらのうち好ましいものは、
エチレングリコールもしくはジエチレングリコールもし
くはトリエチレングリコールの、モノもしくはジメチル
エーテルである。The compound represented by the general formula (2) in (D) is a mono- or dialkyl of the above ethylene glycols or propylene glycols (eg,
Examples thereof include methyl, ethyl, propyl, butyl) ether, ethylene oxide and propylene oxide copolymers of n-butanol, and the like. Of these, the preferred one is
A mono- or dimethyl ether of ethylene glycol or diethylene glycol or triethylene glycol.
【0012】(D)のうち一般式(3)で表される化合
物としては、グリセリンのエチレンオキシド付加重合
物、グリセリンのプロピレンオキシド付加重合物及びグ
リセリンのエチレンオキシド及びプロピレンオキシド付
加共重合物が挙げられる。これらのうち好ましいもの
は、グリセリンのエチレンオキシド付加重合物及びグリ
セリンのエチレンオキシド及びプロピレンオキシド付加
共重合物である。Examples of the compound represented by the general formula (3) in (D) include ethylene oxide addition polymer of glycerin, propylene oxide addition polymer of glycerin, and ethylene oxide and propylene oxide addition copolymer of glycerin. Of these, preferred are ethylene oxide addition polymers of glycerin and ethylene oxide and propylene oxide addition copolymers of glycerin.
【0013】また、(D)のうち一般式(4)で表され
る化合物としては、2−メチル−2,4−ペンタンジオ
ール、2,4−ジメチル−2,4−ペンタンジオール、
2,5−ジメチル−2,5−ヘキサンジオールが挙げら
れる。これらのうち好ましいものは、2−メチル−2,
4−ペンタンジオールである。Further, among the compounds represented by the general formula (4) in (D), 2-methyl-2,4-pentanediol, 2,4-dimethyl-2,4-pentanediol,
2,5-dimethyl-2,5-hexanediol may be mentioned. Among these, preferred is 2-methyl-2,
It is 4-pentanediol.
【0014】本発明の指示薬を構成する各成分の含有量
について説明する。本発明の指示薬中の過酸化物
(A)、ベンジジン系発色剤(B)及び該可溶化剤
(D)の各濃度は、測定方法及び発色反応を進めるため
の条件によって最適濃度が設定されなくてはならない。
また、これら(A)、(B)及び(D)の相互の濃度の
バランスも考慮するとよい。これらの前提はあるが、本
発明の指示薬中の各成分の含有量のうち、該過酸化物
(A)は通常0.005〜5.0mg/ml、好ましく
は0.05〜0.2mg/mlである。該発色剤(B)
は、通常0.01〜10.0mg/ml、好ましくは
0.03〜2.0mg/mlである。該可溶化剤(D)
は通常5.0〜800mg/ml、好ましくは50.0
〜500mg/mlである。The content of each component constituting the indicator of the present invention will be described. The respective concentrations of the peroxide (A), the benzidine color-developing agent (B) and the solubilizing agent (D) in the indicator of the present invention are not optimal depending on the measuring method and the conditions for promoting the color-developing reaction. must not.
Further, it is preferable to consider the balance of the mutual concentrations of these (A), (B) and (D). Although there are these premise, the content of each component in the indicator of the present invention, the peroxide (A) is usually 0.005-5.0 mg / ml, preferably 0.05-0.2 mg / ml. ml. The color former (B)
Is usually 0.01 to 10.0 mg / ml, preferably 0.03 to 2.0 mg / ml. The solubilizer (D)
Is usually 5.0 to 800 mg / ml, preferably 50.0
~ 500 mg / ml.
【0015】本発明の指示薬を用いた過酸化物分解性物
質(C)の測定は、酸性サイド(pH2.5〜6.5)
で行われることが好ましく、特にpH3.0〜5.5で
測定すると安定で良好な発色度が得られる。発色反応の
場として用いられる緩衝液は前記のpHを満足させるも
のであればどのような種類の緩衝液を用いることも可能
であるが、フタル酸水素カリウム/水酸化ナトリウム緩
衝液、クエン酸二ナトリウム/塩酸緩衝液、クエン酸二
水素カリウム/水酸化ナトリウム緩衝液、コハク酸/四
ホウ酸ナトリウム緩衝液、クエン酸水素カリウム/四ホ
ウ酸ナトリウム緩衝液、リン酸水素ナトリウム/クエン
酸緩衝液、酢酸ナトリウム/塩酸緩衝液、酢酸/酢酸ナ
トリウム緩衝液等が挙げられる。この際、好ましい緩衝
液濃度は0.1〜100mM、特に1〜50mMであ
る。The measurement of the peroxide decomposable substance (C) using the indicator of the present invention was carried out on the acidic side (pH 2.5 to 6.5).
Is preferable, and particularly when measured at pH 3.0 to 5.5, stable and good color development is obtained. As the buffer solution used as the place for the color development reaction, any kind of buffer solution can be used as long as it satisfies the above pH, but potassium hydrogen phthalate / sodium hydroxide buffer solution, citrate diacid solution can be used. Sodium / hydrochloric acid buffer, potassium dihydrogen citrate / sodium hydroxide buffer, succinic acid / sodium tetraborate buffer, potassium hydrogen citrate / sodium tetraborate buffer, sodium hydrogen phosphate / citrate buffer, Examples thereof include sodium acetate / hydrochloric acid buffer solution, acetic acid / sodium acetate buffer solution and the like. At this time, the preferable buffer solution concentration is 0.1 to 100 mM, particularly 1 to 50 mM.
【0016】本発明の指示薬の調製方法としては、
(D)に(B)を直接添加してもよく、予め他の溶剤等
に(B)を高濃度に溶解させたものを添加してもよい。
これらに上記緩衝液、過酸化物(A)及び過酸化物分解
性物質(C)を添加し、本発明の指示薬を得るが、特に
これに限定されるものではない。The method for preparing the indicator of the present invention is as follows:
(B) may be added directly to (D), or one obtained by previously dissolving (B) in a high concentration in another solvent or the like may be added.
The above-mentioned buffer solution, peroxide (A) and peroxide decomposable substance (C) are added to these to obtain the indicator of the present invention, but it is not particularly limited thereto.
【0017】発色反応を行う際の温度は(C)の反応に
最も適した温度(ペルオキシダーゼ等の酵素の場合、通
常20〜50℃)で実施することが好ましい。The color development reaction is preferably carried out at a temperature most suitable for the reaction (C) (in the case of an enzyme such as peroxidase, it is usually 20 to 50 ° C.).
【0018】測定の対象となる過酸化物分解性物質
(C)は遊離の状態でも、(C)により免疫活性物質な
どの結合性物質(例えば抗原、抗体、一本鎖核酸、ハプ
テン、プロテインA、アビジン及びビオチン)が標識さ
れた状態でもよく、この標識物質が更に他の物質と結合
後の複合体の状態であってもよい。Even if the peroxide-decomposing substance (C) to be measured is in a free state, the binding substance (eg, antigen, antibody, single-stranded nucleic acid, hapten, protein A) such as an immunoreactive substance can be obtained depending on (C). , Avidin and biotin) may be labeled, or the labeled substance may be in a complex state after binding with another substance.
【0019】本発明の試薬キットは、過酸化物分解性物
質(C)もしくは(C)で標識された物質とともに、少
なくとも本発明の指示薬もしくは本発明の指示薬の各構
成成分を構成品とするものである。ここで標識する物質
としては、上記に例示したような免疫活性物質などの結
合性物質を用いることができる。本発明の指示薬は、保
存安定性がよいため、この様に、本発明の試薬キットの
構成品とすることができ、そうすれば、従来のように指
示薬の各成分を使用の都度配合しなくともよい利点があ
る。また、本発明の指示薬の各成分の状態で本発明のキ
ットの構成品とすることもでき、使用時の配合は必要で
あるが、それでも、配合後の安定性が増加する等の利点
がある。The reagent kit of the present invention comprises, as components, at least the indicator of the present invention or each component of the indicator of the present invention, together with the peroxide decomposable substance (C) or a substance labeled with (C). Is. As the substance to be labeled here, a binding substance such as the immunoactive substance as exemplified above can be used. Since the indicator of the present invention has good storage stability, it can be used as a component of the reagent kit of the present invention in this way, so that each component of the indicator does not need to be blended each time as in the conventional case. There are good advantages. Further, the components of the indicator of the present invention can be used as the components of the kit of the present invention, and it is necessary to mix them at the time of use, but there is still an advantage that the stability after mixing increases. .
【0020】以下、酵素免疫測定に利用される例とし
て、「酵素標識抗体」及び「本発明の指示薬」を構成品
として含むキットの例を挙げる。試験管、ガラスビー
ズ、プラスチックビーズ、マイクロパーティクル、ナイ
ロン膜、濾紙等の固相担体に抗体を予め結合させてお
く。これに試料を加え、測定対象物質である抗原と最初
の反応を行い、“担体結合抗体−抗原”の複合体を形成
する。未反応物を除去し、次に、先の複合体に親和性の
ある「酵素標識抗体」を加え、二番目の反応を行い、
“担体結合抗体−抗原−酵素標識抗体”なる複合体を形
成する。再度未反応物を除去し、最終的に担体に結合し
た酵素と本発明の指示薬と反応させ吸光度を測定する。
この吸光度は試料中の測定対象物質の量に比例するの
で、既知濃度の標準物質を測定して作成した検量線から
試料中の測定対象物質量を求めることができる。[0020] As an example used in the enzyme immunoassay, an example of a kit containing the "enzyme-labeled antibody" and the "indicator of the present invention" as components will be given below. The antibody is bound in advance to a solid support such as a test tube, glass beads, plastic beads, microparticles, nylon membrane, filter paper. A sample is added to this, and the first reaction is performed with the antigen that is the substance to be measured to form a "carrier-bound antibody-antigen" complex. Unreacted material is removed, then "enzyme-labeled antibody" that has an affinity for the complex is added, and a second reaction is performed.
A complex "carrier-bound antibody-antigen-enzyme labeled antibody" is formed. The unreacted material is removed again, and the enzyme bound to the carrier is finally reacted with the indicator of the present invention to measure the absorbance.
Since this absorbance is proportional to the amount of the substance to be measured in the sample, the amount of the substance to be measured in the sample can be obtained from the calibration curve prepared by measuring the standard substance having a known concentration.
【0021】本発明の試薬キットは、例えば、酵素免疫
反応を利用し、α-フェトプロテイン(AFP)、癌胎
児性蛋白(CEA)、フェリチン等の腫瘍マーカー、甲
状腺刺激ホルモン(TSH)、黄体形成ホルモン(L
H)、卵胞刺激ホルモン(FSH)、インシュリン等の
ホルモン、コルチゾール、トリヨードサイロニン(T
3)、サイロキシン(T4)等のハプテンホルモン、ジゴ
キシン、テオフィリン等の薬物、細菌、ウイルス等の感
染性物質、肝炎抗体等に利用することができるが、必ず
しもこれに限定されるものではない。The reagent kit of the present invention utilizes, for example, an enzyme immunoreaction, α-fetoprotein (AFP), carcinoembryonic protein (CEA), tumor markers such as ferritin, thyroid stimulating hormone (TSH), luteinizing hormone. (L
H), follicle stimulating hormone (FSH), hormones such as insulin, cortisol, triiodothyronine (T
3), hapten hormones such as thyroxine (T4), drugs such as digoxin and theophylline, infectious substances such as bacteria and viruses, hepatitis antibodies and the like, but not limited thereto.
【0022】また、酵素免疫測定以外の検査試薬とし
て、「本発明の指示薬」を構成品として含むヘモグロビ
ン定量試薬キットの例を挙げる。「本発明の指示薬」、
過酸化ストロンチウムを混合する。その後、ヘモグロビ
ンを含む試料を添加して、一定時間反応する。吸光度を
ブランクを対照として測定する。既知濃度のヘモグロビ
ンを測定して作成した検量線から、試料中のヘモグロビ
ンの濃度を求める。As a test reagent other than the enzyme immunoassay, an example of a hemoglobin quantitative reagent kit containing the "indicator of the present invention" as a component is given. "Indicator of the invention",
Mix strontium peroxide. Then, a sample containing hemoglobin is added and reacted for a certain period of time. Absorbance is measured using the blank as a control. The concentration of hemoglobin in the sample is obtained from the calibration curve created by measuring hemoglobin of known concentration.
【0023】[0023]
【実施例】以下実施例により本発明を更に説明するが、
本発明はこれに限定されるものではない。また、本発明
の指示薬は必要に応じて、種々の添加剤(例えば、キレ
ート剤のような安定剤、腐敗を防ぐ殺菌剤及び防腐剤、
界面活性剤、着色剤、消泡剤等)を添加することも可能
である。The present invention will be further described with reference to the following examples.
The present invention is not limited to this. Further, the indicator of the present invention, if necessary, various additives (eg, stabilizers such as chelating agents, bactericides and antiseptics to prevent decay,
It is also possible to add a surfactant, a colorant, an antifoaming agent, etc.).
【0024】実施例1 1) 指示薬[1]〜[15]の調製 以下の組成のものを下記表1のように調製し、それぞれ
指示薬[1]〜[15]を得た。 30mMクエン酸緩衝液(pH5.1) 可溶化剤 5%過酸化水素水 3,3’,5,5’−テトラメチルベンジジン溶液
(3,3’,5,5’−テトラメチルベンジジン(同仁
化学製)をアセトンに溶解して200mg/mlに調製
したもの) Example 1 1) Preparation of indicators [1] to [15] The following compositions were prepared as shown in Table 1 below to obtain indicators [1] to [15], respectively. 30 mM citrate buffer (pH 5.1) solubilizer 5% hydrogen peroxide solution 3,3 ′, 5,5′-tetramethylbenzidine solution (3,3 ′, 5,5′-tetramethylbenzidine (Dojindo Kagaku) (Manufactured) was dissolved in acetone to prepare 200 mg / ml)
【0025】[0025]
【表1】 [Table 1]
【0026】2) 比較の指示薬[比1]及び[比2]の
調製 可溶化剤としてメタノール又は1−メチル−2−ピロリ
ドンを用いた以外は上記と同様の方法でそれぞれ比較の
指示薬[比1]及び[比2]を得た。下記表2に示す。2) Comparative indicators [ratio 1] and [ratio 2]
Comparative indicators [ratio 1] and [ratio 2] were obtained in the same manner as above except that methanol or 1-methyl-2-pyrrolidone was used as the prepared solubilizer. It is shown in Table 2 below.
【0027】[0027]
【表2】 [Table 2]
【0028】3) 3,3’,5,5’−テトラメチルベ
ンジジンに対する可溶化剤の効果 指示薬の調製後の安定性(溶解性)を比較するため、指
示薬[1]〜[15]及び[比1]、[比2]を調製直
後より1週間、1ケ月及び1年、4℃で保存し、結晶析
出の有無を調べた結果を下記表3に示す。3) 3,3 ', 5,5'-tetramethylbe
Effect of solubilizers on benzidine In order to compare the stability (solubility) of the indicators after preparation, indicators [1] to [15] and [ratio 1] and [ratio 2] were used for 1 week and 1 month immediately after preparation. Table 3 below shows the results of examining the presence or absence of crystal precipitation after storage at 4 ° C for 1 year.
【0029】[0029]
【表3】 [Table 3]
【0030】実施例2 1) ペルオキシダーゼ溶液(POD溶液と略す)の調製 1%牛血清アルブミン、0.85%NaCl、pH7.
2、0.02Mリン酸緩衝液(以下PBSと略す)1m
lに、ペルオキシダーゼ(以下PODと略す。東洋紡
製)0.5mgを溶解し、さらに、PBSで500倍に
希釈してPOD溶液(1μg/ml)を得た。 Example 2 1) Preparation of peroxidase solution (abbreviated as POD solution) 1% bovine serum albumin, 0.85% NaCl, pH 7.
2, 0.02M phosphate buffer (hereinafter abbreviated as PBS) 1m
0.5 mg of peroxidase (hereinafter abbreviated as POD; manufactured by Toyobo) was dissolved in 1 and further diluted 500 times with PBS to obtain a POD solution (1 μg / ml).
【0031】2) 指示薬のブランク試験 実施例1出調製した指示薬[3]、[6]、[14]及
び[比1]、[比2]の650nmの吸光度を分光光度
計(島津製作所製、UV−160A)を用いて、水を対
照にして測定した。更に、同様の指示薬を4℃及び25
℃において、1、3、6ケ月間それぞれ保存したものに
ついても、同様に水を対照にしてブランクを測定した。
結果を下記表4に示す。2) Blank test of indicator Example 1 The spectrophotometer (manufactured by Shimadzu Corp.) was used to measure the absorbance of the prepared indicators [3], [6], [14] and [ratio 1], [ratio 2] at 650 nm. UV-160A) was used to measure water as a control. In addition, a similar indicator at 4 ° C and 25
With respect to the samples stored at 1, 3, 6 months respectively, blanks were similarly measured using water as a control.
The results are shown in Table 4 below.
【0032】[0032]
【表4】 [Table 4]
【0033】実施例3 1) 指示薬の発色度試験 実施例1で調製した指示薬[3]、[6]、[14]及
び[比1]、[比2]各300μlに、POD溶液を5
0μl添加し、37℃、15分間反応させた。その後、
分光光度計を用いて、650nmの発色度を測定した。
更に、4℃及び25℃において、1、3、6ケ月間それ
ぞれ保存した同様の指示薬についてもPOD溶液を反応
させ、POD溶液の代わりに水を添加して反応させた液
を対照として吸光度を測定した。その結果を下記表5に
併せて示す。 Example 3 1) Color development test of indicator Each of the indicators [3], [6], [14] and [ratio 1], [ratio 2] 300 μl prepared in Example 1 was treated with 5 parts of POD solution.
0 μl was added, and the mixture was reacted at 37 ° C. for 15 minutes. afterwards,
Using a spectrophotometer, the degree of color development at 650 nm was measured.
Furthermore, at 4 ° C and 25 ° C, the POD solution was also reacted with the same indicator stored for 1, 3 and 6 months respectively, and the absorbance was measured using the solution reacted by adding water instead of the POD solution as a control. did. The results are also shown in Table 5 below.
【0034】[0034]
【表5】 [Table 5]
【0035】[0035]
【発明の効果】本発明の指示薬は次のような顕著な効果
を奏する。 (1)本発明の指示薬は保存安定性が良好なので、試薬
キットの構成品とすることができる。従来の指示薬は、
調製後不安定で、発色剤が析出する、ペルオキシダーゼ
等の過酸化物分解性物質不存在下にも拘らず、発色する
(ブランク値が上昇する)、発色度が低下するため、使
用直前に調製しなければならない等の問題があったのを
解決するものである。 (2)表面張力が低下し、機器測定による精度が上昇す
る。The indicator of the present invention has the following remarkable effects. (1) Since the indicator of the present invention has good storage stability, it can be used as a component of a reagent kit. Conventional indicators are
It is unstable after preparation, and the color former precipitates, and color develops (blank value increases) even in the absence of peroxide-decomposable substances such as peroxidase, and the degree of coloration decreases, so it is prepared immediately before use. It solves the problem of having to do. (2) The surface tension is reduced, and the accuracy measured by the device is increased.
Claims (6)
ジン系発色剤(B)を溶解させてなり、過酸化物分解性
物質(C)の測定を(A)と(C)との反応に伴う
(B)の発色により行うことができる指示薬において、
更に下記一般式(1)〜(4)で表される化合物から選
ばれる少なくとも1種の可溶化剤(D)を含有すること
を特徴とする過酸化物分解性物質測定用指示薬。 (式中、R1はそれぞれ独立に炭素数2〜4のアルキレ
ン基、R2は炭素数1〜4のアルキル基、 R3は水素又
は炭素数1〜4のアルキル基、 R4は炭素数1〜4のア
ルキレン基、R5はそれぞれ独立に水素または炭素数1
〜4のアルキル基、mは2〜20の整数、nは1〜20
の整数、X+Y+Zは1〜20の整数である)1. A method in which a peroxide-decomposable substance (C) is prepared by dissolving a peroxide (A) and a benzidine-based color former (B) in an aqueous medium. In the indicator which can be performed by the color development of (B) accompanying the reaction,
An indicator for measuring a peroxide decomposable substance, which further comprises at least one solubilizer (D) selected from compounds represented by the following general formulas (1) to (4). (In the formula, R 1 is each independently an alkylene group having 2 to 4 carbon atoms, R 2 is an alkyl group having 1 to 4 carbon atoms, R 3 is hydrogen or an alkyl group having 1 to 4 carbon atoms, and R 4 is a carbon number. 1-4 alkylene groups, R 5 is independently hydrogen or C 1
~ 4 alkyl group, m is an integer of 2-20, n is 1-20
, X + Y + Z is an integer of 1 to 20)
である請求項1記載の指示薬。2. The content of (D) is 5 to 800 mg / ml.
The indicator according to claim 1, which is
チルベンジジンである請求項1又は2記載の指示薬。3. The indicator according to claim 1, wherein (B) is 3,3 ′, 5,5′-tetramethylbenzidine.
/mlである請求項1〜3のいずれか記載の指示薬。4. The content of (B) is 0.01 to 10.0 mg.
The indicator according to any one of claims 1 to 3, which is / ml.
1〜4のいずれか記載の指示薬。5. The indicator according to claim 1, wherein (C) is peroxidase.
(C)で標識された物質を構成品として含む試薬キット
において、少なくとも請求項1〜5のいずれか記載の指
示薬もしくはこの指示薬の各成分を共に構成品とするこ
とを特徴とする試薬キット。6. A reagent kit comprising a peroxide decomposable substance (C) or a substance labeled with (C) as a constituent, at least the indicator according to any one of claims 1 to 5 or each component of the indicator. A reagent kit, characterized in that both are components.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4084908A JPH07114712B2 (en) | 1992-03-06 | 1992-03-06 | Indicator and reagent kit for measuring peroxide-decomposable substances |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4084908A JPH07114712B2 (en) | 1992-03-06 | 1992-03-06 | Indicator and reagent kit for measuring peroxide-decomposable substances |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0622794A true JPH0622794A (en) | 1994-02-01 |
| JPH07114712B2 JPH07114712B2 (en) | 1995-12-13 |
Family
ID=13843839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4084908A Expired - Lifetime JPH07114712B2 (en) | 1992-03-06 | 1992-03-06 | Indicator and reagent kit for measuring peroxide-decomposable substances |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH07114712B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007093399A (en) * | 2005-09-29 | 2007-04-12 | Miura Co Ltd | Residual chlorine concentration measurement composition |
| CN103884563A (en) * | 2014-04-10 | 2014-06-25 | 上海太阳生物技术有限公司 | Peroxidase (POX) staining solution (chemical staining method) |
| US10597352B1 (en) * | 2019-02-23 | 2020-03-24 | OneStep Technologies Inc. | Stable alkyl benzidine composition and methods of making and using same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61500686A (en) * | 1983-11-04 | 1986-04-10 | インミユ−ノ コンセプツ インコ−ポレ−テツド | Stabilization of indicators for enzyme activity detection |
-
1992
- 1992-03-06 JP JP4084908A patent/JPH07114712B2/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61500686A (en) * | 1983-11-04 | 1986-04-10 | インミユ−ノ コンセプツ インコ−ポレ−テツド | Stabilization of indicators for enzyme activity detection |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007093399A (en) * | 2005-09-29 | 2007-04-12 | Miura Co Ltd | Residual chlorine concentration measurement composition |
| CN103884563A (en) * | 2014-04-10 | 2014-06-25 | 上海太阳生物技术有限公司 | Peroxidase (POX) staining solution (chemical staining method) |
| CN103884563B (en) * | 2014-04-10 | 2016-08-17 | 上海太阳生物技术有限公司 | Peroxidase (POX) dyeing liquor (chemical dyeing method) |
| US10597352B1 (en) * | 2019-02-23 | 2020-03-24 | OneStep Technologies Inc. | Stable alkyl benzidine composition and methods of making and using same |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07114712B2 (en) | 1995-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5171668A (en) | Method of the chemiluminescence assay of the activity of peroxidase | |
| CN110146692A (en) | One kind being based on acridinium ester chemiluminescent, Streptavidin MagneSphere-biotin iodine system and detection kit | |
| US5424194A (en) | 4-(cyanomethylthio)phenol enhanced peroxidase assays | |
| EP0321487B1 (en) | Enhanced luminescent assay | |
| EP0618300A1 (en) | TMB formulation for soluble and precipitable HRP-ELISA | |
| EP0235970A1 (en) | Luminescent analyses with enhanced storage stability | |
| US6251618B1 (en) | Color developing method, enzyme immunoassay using the color developing method, and immunochromatography incorporating the enzyme immunoassay | |
| EP0152847B1 (en) | Stabilized enzyme conjugate composition | |
| JPH07114712B2 (en) | Indicator and reagent kit for measuring peroxide-decomposable substances | |
| IE904418A1 (en) | Buffered wash composition, insolubilizing composition, test¹kits and method of use | |
| JPH07121235B2 (en) | Indicator and reagent kit for measuring peroxide-decomposable substances | |
| JP2535290B2 (en) | Indicator for measuring peroxide-decomposable substances | |
| JPH0889291A (en) | Indicator for measuring peroxide decomposing substance and reagent kit | |
| AU630376B2 (en) | Method for assaying immunologically active substance and reagent therefor | |
| EP0480361A2 (en) | Quantitation by chemiluminescence using photosenstive substance | |
| CN117720971A (en) | Cleaning solutions and chemiluminescent immunoassay methods for chemiluminescent immunoassays | |
| JPH05227995A (en) | Indicator and reagent kit for determination of peroxide-decomposing substance | |
| CN113533735A (en) | Application of acridinium ester analogue in preparation of acridinium ester analogue labeled antibody | |
| JPH0762679B2 (en) | Indicator and reagent kit for measuring peroxide-decomposable substances | |
| JP2660932B2 (en) | Chemiluminescence assay for peroxidase activity. | |
| JP3776229B2 (en) | Chemiluminescent reagent and method for producing the same | |
| JP3746381B2 (en) | Chemiluminescent enzyme immunoassay method | |
| JPH0638757B2 (en) | Peroxidase or H ▲ lower 2 ▼ O ▲ lower 2 ▼ measuring method | |
| JP3745112B2 (en) | Chemiluminescent enzyme immunoassay method | |
| JP4286357B2 (en) | Chemiluminescent enzyme immunoassay method |